Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl) phenyl]-5-methyl-monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation

Biochemical Pharmacology

Volumn 56, Issue 8, 1998, Pages 1065-1073

  Johnson Mills, Karen ^a   Arauz, Elizabeth ^a   Coffey, Ronald G ^a   Krzanowski Jr, Joseph J ^a   Polson, James B ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

3',5' cyclic nucleotide phosphodiesterase; cyclic AMP; Human coronary artery smooth muscle cells; Phosphodiesterase inhibitors; Vascular smooth muscle cells

Indexed keywords

4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE; ROLIPRAM;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CORONARY ARTERY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ADULT; CELL DIVISION; CELLS, CULTURED; CORONARY VESSELS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; PYRROLIDINONES; ROLIPRAM;

EID: 0032531719     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00239-1     Document Type: Article

References (29)

1. Ip J.H., Fuster V., Badimon L., Badimon J., Taubman M.B., Chesebro J.H. Syndromes of accelerated atherosclerosis Role of vascular injury and smooth muscle cell proliferation . J Am Coll Cardiol. 15:1990;1667-1687.
2. Campbell G.R., Campbell J.H. Recent advances in molecular pathology. Smooth muscle phenotypic changes in arterial wall homeostasis Implications for the pathogenesis of atherosclerosis . Exp Mol Pathol. 42:1985;139-162.
3. Ross R. The pathogenesis of atherosclerosis - An update. N Engl J Med. 314:1986;488-500.
4. Abell C.W., Monohan T.M. The role of adenosine 3′,5′-cyclic monophosphate in the regulation of mammalian cell division. J Cell Biol. 59:1973;549-558.
5. Berridge M.J. The interaction of cyclic nucleotides and calcium in the control of cellular activity. Adv Cyclic Nucleotide Res. 6:1975;1-98.
6. Coffino P., Gray J.W., Tomkins G.M. Cyclic AMP, a nonessential regulator of the cell cycle. Proc Natl Acad Sci USA. 72:1975;878-882.
7. Pardee A.B., Dubrow R., Hamlin J.L., Kletzien R.F. Animal cell cycle. Annu Rev Biochem. 47:1978;715-750.
8. Jonzon B., Nilsson J., Fredholm B.B. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J Cell Physiol. 124:1985;451-456.
9. 1. Exp Cell Res. 160:1985;117-125.
10. 2 in cultured rabbit aortic smooth muscle cells. Atherosclerosis. 71:1988;165-171.
11. 2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol. 37:1990;30-36.
12. Appleman M.M., Terasaki W.L. Regulation of cyclic nucleotide phosphodiesterase. Adv Cyclic Nucleotide Res. 5:1975;153-162.
13. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 46:1994;399-405.
14. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interaction between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 48:1994;827-835.
15. Souness J.E., Hassal G.A., Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 44:1992;857-866.
16. Kunishima T., Musha H., Eto F., Iwasaki T., Nagashima J., Masui Y., So T., Nakamura T., Oohama N., Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 19:1997;1058-1066.
17. Johnson K., Arauz E., Krzanowski J.J., Polson J.B. Effect of PDE3 and PDE4 inhibitors on the proliferation of human coronary artery smooth muscle cells. FASEB J. 11:1997;A151.
18. Johnson-Mills K, Coffey RG, Arauz E, Krzanowski JJ and Polson JB, Effects of CI-930 and rolipram on cyclic AMP levels in human coronary artery smooth muscle cells. FASEB J 12: A155, 1998.
19. Mohler W.A., Charlton C.A., Blau H.M. Spectrometric quantitation of tissue culture cell number in any medium. Biotechniques. 21:1996;260-266.
20. Thompson W.J., Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry. 10:1971;311-316.
21. Robicsek S.A., Krzanowski J.J., Szenitvanyi A., Polson J.B. High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human lymphocytes. Biochem Biophys Res Commun. 163:1989;554-560.
22. Coffey R.G., Hadden E.M., Hadden J.W. Phytohemagglutinin stimulation of guanylate cyclase in human lymphocytes. J Biol Chem. 256:1981;4418-4424.
23. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 266:1994;L536-L543.
24. Xiong Y., Westhead E.W., Slakey L.L. Role of phosphodiesterase isoenzyme in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem J. 305:1995;627-633.
25. Ross R., Glomset J.A. The pathogenesis of atherosclerosis. N Engl J Med. 295:1976;369-377.
26. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 57:1995;791-804.
27. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 36:1996;403-427.
28. Indolfi C., Vittorio E., Di Lorenzo E., Esposito G., Rapacciulo A., Guiliano P., Grieco D., Cavuto L., Stingone A.M., Ciullo I., Condorelli G., Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 3:1997;775-779.
29. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J Pharmacol Exp Ther. 247:1988;34-42.